PROCEPT BioRobotics Corporation (PRCT)
After hours:
| Previous Close | 60.61 |
| Open | 62.63 |
| Bid | 61.68 x 100 |
| Ask | 61.83 x 200 |
| Day's Range | 59.27 - 62.90 |
| 52 Week Range | 24.83 - 63.26 |
| Volume | |
| Avg. Volume | 537,575 |
| Market Cap | 3.173B |
| Beta (5Y Monthly) | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.24 |
| Earnings Date | Jul 25, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.43 |
Investor's Business DailyBiotech Leader Procept BioRobotics Surges Past Buy Point On Earnings
Procept Stock: Biotech leader Procept BioRobotics is breaking out past its latest buy point. Shares jumped on Q1 earnings results Wednesday.
ZacksPROCEPT BioRobotics Corporation (PRCT) Reports Q1 Loss, Tops Revenue Estimates
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 7.27% and 6.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswirePROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables revenue of $23.6 mi
